Neuroendocrine serum tumour markers in hormone-resistant prostate cancer
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer
复制标题
DOI：
10.1016/s0302-2838(03)00257-4
复制
发表时间：
2003-08-01
期刊：
影响因子：
23.4
通讯作者：
Fosså, SD
中科院分区：
文献类型：
--
作者：
Hvamstad, T;Jordal, A;Fosså, SD
目的：该研究的主要目的是评估血清神经元特异性烯醇化酶（NSE）和嗜铬粒蛋白A（CgA）水平升高在耐药前列腺癌（HRPC）中的患病率，并评估这些标志物的预后意义。其次，我们希望评估姑息性放疗后血清NSE或CgA水平的任何变化。方法：对因HRPC引起的疼痛性骨转移或症状性盆腔肿瘤患者的血清样本进行姑息性放疗前后前列腺特异性抗原（PSA）、NSE和CgA的分析。放疗前NSE升高者46例（33%），CgA升高者80例（58%），两者之间无相关性，与PSA无相关性。放疗后，NSE水平中位数显著降低（p = 0.004），而CgA（p = 0.009）和PSA（p = 0.019）升高。在多变量生存分析中，降低的性能状态，骨扫描> 20个骨转移，低血红蛋白，放疗前升高的NSE水平表明一个短survival.Conclusion：连同已知的临床参数，NSE预测生存与HRPC患者。NSE可能成为一个有价值的预后指标在这种情况下的患者。(C)2003 Elsevier B.V.保留所有权利。
Objective: The primary aim of the study was to assess the prevalence of elevated serum levels of neuron-specific enolase (NSE) and chromogranin A (CgA) in hormone-resistant prostate cancer (HRPC), and to evaluate these markers' prognostic significance. Secondarily we wanted to assess any change in serum levels of NSE or CgA after palliative radiotherapy.Methods: Serum samples from patients with painful bone metastases or symptomatic pelvic tumours due to HRPC were analyzed for prostatespecific antigen (PSA), NSE and CgA before and after palliative radiotherapy.Results: Forty-six of 138 patients (33%) had elevated NSE before radiotherapy, while 80 (58%) had elevated CgA, without correlation between the two markers or with PSA. After radiotherapy the median NSE level was significantly reduced (p = 0.004), whereas CgA (p = 0.009) and PSA (p = 0.019) increased. In the multivariate survival analysis, a reduced performance status, >20 bone metastases on bone scan, low hemoglobin, and pre-radiotherapy elevated NSE levels indicated a short survival.Conclusion: Together with known clinical parameters, NSE predicts survival in patients with HRPC. NSE could become a valuable prognostic marker in patients with this condition. (C) 2003 Elsevier B.V. All rights reserved.